Multimerization and conjugation of nanobodies with an antiviral agent enhance their antiviral activity
Researchers from the IBCh RAS, in collaboration with colleagues from the IGB RAS and the Gamaleya Center, have developed a novel strategy for anti-SARS-Cov-2 nanobodies modification. The potential to enhance the activity of three VHH antibodies specific to the receptor-binding domain of the SARS-CoV-2 spike protein were investigated. Tetramerization of nanobodies and their fusion with the Fc domain substantially increased the affinity of these molecules for the viral protein, while conjugation with the small-molecule antiviral compound ARVI11 resulted in a pronounced enhancement of neutralizing activity compared to the original monomeric proteins. Nanobody multimerization and targeted delivery of antiviral molecules opens new avenues for the development of new antiviral agents. The results are published in ACS Omega.
30 июля